Companies Dominating the Genetic Cardiomyopathies Market
- Becton Dickinson and Company
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Novartis International AG
- Merck & Co.
- Teva Pharmaceuticals Industries Ltd.
- Bristol Myers Squibb Company
- Mylan N.V.
- Boston Scientific Corporation
- Critical Care Diagnostics Inc.
- Bio-Rad Laboratories Inc.
- Sanofi S.A
- Roche Holding AG
- Astella Pharma
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of genetic cardiomyopathies is estimated at USD 2.51 billion.
The genetic cardiomyopathies market size was valued at USD 2.26 billion in 2024 and is likely to cross USD 11.33 billion by 2037, expanding at more than 13.2% CAGR during the forecast period i.e., between 2025-2037. Increasing need for early detection and growing development of gene therapies will drive the market growth.
North America industry is anticipated to hold largest revenue share of 38% by 2037, impelled by growing research & development of gene therapies in the region.
The major players in the market are Novartis International AG, Merck & Co., Teva Pharmaceuticals Industries Ltd., Bristol Myers Squibb Company, Mylan N.V., Boston Scientific Corporation, Critical Care Diagnostics Inc., Bio-Rad Laboratories Inc., Roche Holding AG, AstraZeneca PLC, and Sanofi S.A
